Correction: Comparative analysis of cutaneous features of psoriasis in acute and chronic imiquimod-induced mouse models
Emma Fraillon, Jean-François Jégou, Hanitriniaina Rabeony, Jean-Claude Lecron, Nicolas Lebonvallet, Emilie Marie-Joseph, Audrey Josset-Lamaugarny, Géraldine Aimond, Laurent Misery, Franck Morel, Fabien P. Chevalier, Bérengère Fromy
Abstract
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 2Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsPsoriasis: Treatment and Pathogenesis · Nonmelanoma Skin Cancer Studies · Genetic and rare skin diseases.
Correction to: Scientific Reports 10.1038/s41598-025-12111-6, published online 23 July 2025
The original version of this Article contained an error in Fig. 2, where statistics were missing. The original Fig. 2 and accompanying legend appear belowFig. 2Effects of IMQ on the gene expression levels of pro-inflammatory mediators and epidermal markers after ST and LT treatments. Pro-inflammatory mediators (IL-17A (A), IL-1α (B), CXCL3 (C)), AMPs (BD3 (D)) and epidermal markers (KRT6 (E), KRT10 (F), IVL (G), KLK5 (H)) gene expression was assessed by RT-qPCR on total mRNAs from mouse back skin collected 24 h after the last Vaseline or IMQ application, and normalized with GAPDH (ST-Vaseline n = 25, ST-IMQ n = 32, LT-Vaseline n = 28, LT-IMQ n = 26). A Two-Way ANOVA with Bonferroni’s correction was performed to compare each mediator expression after ST and LT treatments either with Vaseline or IMQ.
The original Article has been corrected.